WINDLAS BIOTECH
|
The Current P/E Ratio of WINDLAS BIOTECH is 30.76.
| Share Price | ₹992.3 | Aug 24,2026 |
| Market Cap | ₹2,044.1 Cr | |
| Earnings-TTM | ₹66.5 Cr | TTM-Consolidated Results |
| Price/Earnings | 30.76x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of WINDLAS BIOTECH
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹2,044.1 Cr] as on Aug 24,2026
(/) Earnings [ ₹66.5 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 30.76x ]
Thus, for WINDLAS BIOTECH , the investors are currently willing to pay 30.76 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of WINDLAS BIOTECH !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of WINDLAS BIOTECH over the last five years.
Historical PE (Price/Earnings) ratio chart of WINDLAS BIOTECH
PE Ratio Performance Analysis for WINDLAS BIOTECH
- WINDLAS BIOTECH 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 20.12x.
- WINDLAS BIOTECH 's operated at median p/e ratio of 18.31x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, WINDLAS BIOTECH 's p/e ratio peaked in Mar2025 at 35.78x.
- WINDLAS BIOTECH 's p/e ratio hit its five-year low in Mar2023 of 11.06x.
How does WINDLAS BIOTECH 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| WINDLAS BIOTECH | 66.46 | 30.76 | 2,044.1 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 12,172.70 | 37.65 | 458,249.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 77.14 | 225,648.0 |
| TORRENT PHARMACEUTICALS LTD | 2,156.00 | 85.76 | 184,891.0 |
| CIPLA LTD | 3,364.84 | 34.45 | 115,927.0 |
| DR REDDYS LABORATORIES LTD | 3,169.30 | 31.46 | 99,702.0 |
| MANKIND PHARMA LTD | 2,055.11 | 47.73 | 98,086.5 |
| LUPIN LTD | 5,551.01 | 18.04 | 100,134.0 |
| ZYDUS LIFESCIENCES LTD | 4,492.20 | 24.45 | 109,825.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 24.94 | 92,612.8 |
| LAURUS LABS LTD | 1,090.76 | 88.98 | 97,053.6 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs WINDLAS BIOTECH 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.04x |
| Max industry PE | 88.98x |
| Median industry PE | 34.45x |
| Average industry PE | 45.58x |
You may also like the below Video Courses